Vivia Biotech, Compound Profiling and Translational CRO to enable Cancer Drug and Biomarker Discovery & Development
We have more than 10 years of experience working with top pharma, biotech and other life science organizations.
Our assays cover many aspects of primary cell biology with a special emphasis on preserving native microenvironment in hematological ex vivo (blood and marrow) systems. Follow the links for more information.
We count on high qualified expertise from our dedicated staff, external consultants and collaborators.
We can also adapt to your specific needs, please contact us to discuss your project requirements.
-
Combined Functional and Molecular Studies
-
NGS methods
-
Compound Profiling by Flow Cytometry
-
Data Analysis for Molecular Biology Assays
-
Advanced Analysis and Visualization through TIBCO Spotfire
Vivia performs feasibility studies to accurately foresee the collection timelines, and puts its own experience, together with our collaborators’s clinical expertise at our customers’ disposal to help you improve your research lines and results.
Vivia’s standard procedures guarantees the suitability and highest quality of samples with a variety of features for our customer’s research. All samples and clinical data from patients who meet the predefined inclusion and exclusion criteria are collected in accordance with GCP guidelines and applicable laws, within the approval framework of the competent Ethics Committee and after patient’s declared consent.
Vivia offers to its partners proprietary Native Environment Assays in patient’s whole bone marrow, assessing the drug activity in the native tumor microenvironment:
- Assays include state of the art immune-oncology (IO drugs, CAR-T), and microenvironment assays (BCR inhibitors)
- Key deliveries of PharmaFlow PM for your drug development:
-
Direct impact in ROI over 90% CR in clinical trials as CDxIdentification of early molecular biomarkers of efficacy/resistanceBetter understanding of MOA & interpatient variability of responseBest combos to increase market share & overcome resistance in clinical trialsMarket positioning vs. SOC and competitive drugs